3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
4
Triple Negative Breast Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Solid Tumor, Adult
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Bites and Stings
2
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Oligoprogressive
1
Multiple Myeloma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
First-line Advanced NSCLC Patients
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled